Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study

BMC Health Services Research

Volumn 15, Issue 1, 2015, Pages

  Kourlaba, Georgia ^a   Rapti, Vasiliki ^b   Alexopoulos, Athanasios ^b   Relakis, John ^c   Koumakis, Georgios ^d   Chatzikou, Magdalini ^e   Maniadakis, Nikos ^c   Georgoulias, Vassilis ^f  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HYGEIA HOSPITAL   (Greece)

^c NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^d SAINT SAVVAS HOSPITAL   (Greece)

^e Applications and RandD   (Greece)

^f UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Bevacizumab; Cost effectiveness; Estrogen receptor positive; Everolimus; Metastatic breast cancer

Indexed keywords

ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; EVEROLIMUS; EXEMESTANE; MONOCLONAL ANTIBODY;

BREAST NEOPLASMS; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; GREECE; HUMAN; MIDDLE AGED; QUALITY ADJUSTED LIFE YEAR;

ANDROSTADIENES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; EVEROLIMUS; FEMALE; GREECE; HUMANS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS;

EID: 84938604409     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-015-0971-4     Document Type: Article

References (28)

1. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. International journal of cancer Journal international du cancer. 2013;132:1133-45.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008 v2.0: Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet], Available from: http://globocan.iarc.fr. In Book GLOBOCAN 2008 v2.0: Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet], Available from: http://globocan.iarc.fr (Editor ed.^eds.). City: International Agency for Research on Cancer; 2010.
3. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2012;23:vii11-9.
4. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J clin oncol: off j Am Soc Clin Oncol. 2010;28:3271-7.
5. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-717.
6. Berkowitz N, Gupta S, Silberman G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2000;3:23-30.
7. Legorreta AP, Brooks RJ, Leibowitz AN, Solin LJ. Cost of breast cancer treatment. A 4-year longitudinal study. Arch Intern Med. 1996;156:2197-201.
8. Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst. 1995;87:417-26.
9. Rao S, Kubisiak J, Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat. 2004;83:25-32.
10. Vera-Llonch M, Weycker D, Glass A, Gao S, Borker R, Qin A, et al. Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. BMC Cancer. 2011;11:250-0.
11. Wan Y, Gao X, Mehta S, Wang Z, Faria C, Schwartzberg L. Indirect costs associated with metastatic breast cancer. J Med Econ. 2013;16:1169-78.
12. National Cancer Institute: Breast Cancer Treatment: Stage IV, Recurrent, and Metastatic Breast Cancer [ http://www.cancer.gov/types/breast/hp/breast-treatment-pdq#link/-297-toc ] 10/9/2013
13. Noguchi S, Masuda N, Iwata H, Mukai H, Horiguchi J, Puttawibul P, et al.: Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. Breast Cancer. 2014;21(6):703-14. doi: 10.1007/s12282-013-0444-8. Epub 2013 Feb 13.
14. Dodwell D, Wardley A, Johnston S. Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. Breast (Edinburgh, Scotland). 2006;15:584-94.
15. National Institute for Health and Care Excellence: Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptorpositive breast cancer after endocrine therapy. NICE technology appraisal guidance 295; 2013. https://www.nice.org.uk/guidance/ta295/resources/guidance-everolimus-in-combination-withexemestane-for-treating-advanced-her2negative-hormonereceptorpositive-breast-cancer-after-endocrine-therapy-pdf.
16. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. N Eng J Med. 2012;366:520-9.
17. Yardley DA, Noguchi S, Pritchard KI, Burris 3rd HA, Baselga J, Gnant M, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30:870-84.
18. Wilcken N, Dear R. Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007. European journal of cancer (Oxford, England: 1990). 2008;44:2218-25.
19. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J clin oncol: off j Am Soc Clin Oncol. 2008;26:1642-9.
20. Gonzalez-Angulo AM, Hortobagyi GN. Optimal schedule of paclitaxel: weekly is better. J clin oncol: off j Am Soc Clin Oncol. 2008;26:1585-7.
21. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J clin oncol: off j Am Soc Clin Oncol. 1999;17:485-93.
22. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001;92:1759-68.
23. Venturini M, Paridaens R, Rossner D, Vaslamatzis MM, Nortier JW, Salzberg M, et al. An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer. Oncology. 2007;72:51-7.
24. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. N Eng J Med. 2007;357:2666-76.
25. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J clin oncol: off j Am Soc Clin Oncol. 2011;29:1252-60.
26. Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95:683-90.
27. WHO: Choosing interventions that are Cost Effective (WHO-CHOICE): Cost-effectiveness thresholds [ http://www.who.int/choice/costs/CER-thresholds/en/index.html ]
28. International Monetary Fund: World Economic Outlook Database [ http://www.imf.org/external/pubs/ft/weo/2012/02/weodata/index.aspx ]